Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer

Autor: Koji Arihiro, Morihito Okada, Yoshinori Handa, Yoshihiro Miyata, Yasuhiro Tsutani, Yuichiro Kai, Yukio Takeshima, Takahiro Mimae, Noriyuki Shiroma
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Programmed Cell Death 1 Receptor
Adenocarcinoma of Lung
CD8-Positive T-Lymphocytes
B7-H1 Antigen
03 medical and health sciences
Lymphocytes
Tumor-Infiltrating
0302 clinical medicine
Immune system
Carcinoma
Non-Small-Cell Lung
Internal medicine
PD-L1
Tumor Microenvironment
medicine
Humans
Lung cancer
Aged
Neoplasm Staging
Retrospective Studies
biology
business.industry
Proportional hazards model
Tumor-infiltrating lymphocytes
Hazard ratio
Immunotherapy
Middle Aged
medicine.disease
Survival Rate
030104 developmental biology
030220 oncology & carcinogenesis
biology.protein
Adenocarcinoma
Female
Neoplasm Recurrence
Local
business
Follow-Up Studies
Zdroj: Clinical Lung Cancer. 21:e302-e314
ISSN: 1525-7304
Popis: Background The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune microenvironment has not yet been elucidated. Patients and Methods We retrospectively analyzed 126 patients with pathologic stage I non–small-cell lung cancer. Patients with lepidic-dominant adenocarcinoma were excluded. PD-L1 expression was evaluated with immunohistochemistry correlated with clinicopathologic features and surrounding immune microenvironment status, including CD4, CD8, regulatory T cells, and human leukocyte antigen class I. Factors affecting prognosis were assessed by Kaplan-Meier and Cox regression analyses. Results Twenty-three (18.3%) patients were positive for PD-L1 expression. No significant correlation was observed between PD-L1 expression and the surrounding immune microenvironment status. The PD-L1–positive group had a worse prognosis than the PD-L1–negative group (5-year recurrence-free survival rates, 63.4% vs. 81.0%; P = .061). Among surrounding immune cells, intratumoral CD8 status had the strongest impact on prognosis (P = .12). In the intratumoral CD8–high group, PD-L1 expression demonstrated no significant prognostic impact, whereas in the intratumoral CD8–low group, patients positive for PD-L1 demonstrated a significantly worse prognosis than those negative for PD-L1 (5-year recurrence-free survival rates, 41.7% vs. 78.6%; P = .034). Multivariable Cox regression analysis revealed that ‘PD-L1–positive and intratumoral CD8–low’ status was an independent prognostic factor (hazard ratio, 3.80; 95% confidence interval, 1.22-10.5; P = .023). Conclusions The prognostic impact of the PD-1/PD-L1 pathway may be distinct according to concurrent intratumoral CD8 status.
Databáze: OpenAIRE
Externí odkaz: